{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:26:13Z","timestamp":1792783573610,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T00:00:00Z","timestamp":1505520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T00:00:00Z","timestamp":1505520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA88843"],"award-info":[{"award-number":["P50 CA88843"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000142","name":"Avon Foundation for Women","doi-asserted-by":"publisher","award":["02-2010-048"],"award-info":[{"award-number":["02-2010-048"]}],"id":[{"id":"10.13039\/100000142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["LRTSTBCR07"],"award-info":[{"award-number":["LRTSTBCR07"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["316-2016"],"award-info":[{"award-number":["316-2016"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cindy Rosencrans fund for TNBC","award":["80022485"],"award-info":[{"award-number":["80022485"]}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["drug supply"],"award-info":[{"award-number":["drug supply"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abraxis","award":["drug supply"],"award-info":[{"award-number":["drug supply"]}],"id":[{"id":"https:\/\/ror.org\/05r1gew95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10549-017-4503-2","type":"journal-article","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T04:55:24Z","timestamp":1505537724000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008"],"prefix":"10.1007","volume":"167","author":[{"given":"Roisin M.","family":"Connolly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Fackler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian C.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Storniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley P.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswati","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,16]]},"reference":[{"key":"4503_CR1","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed September 14 2017"},{"issue":"6","key":"4503_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.6004\/jnccn.2015.0088","volume":"13","author":"RA Mukhtar","year":"2015","unstructured":"Mukhtar RA, Wong JM, Esserman LJ (2015) Preventing overdiagnosis and overtreatment: just the next step in the evolution of breast cancer care. J Natl Compr Cancer Netw 13(6):737\u2013743","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"4503_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/CCO.0000000000000324","volume":"28","author":"M Abramovitz","year":"2016","unstructured":"Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B (2016) Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Curr Opin Oncol 28(6):461\u2013468","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"4503_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-016-4014-6","volume":"160","author":"JS Lee","year":"2016","unstructured":"Lee JS, Magbanua MJ, Park JW (2016) Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat 160(3):411\u2013424","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4503_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13058-016-0779-0","volume":"18","author":"C Selli","year":"2016","unstructured":"Selli C, Dixon JM, Sims AH (2016) Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res 18(1):118","journal-title":"Breast Cancer Res"},{"issue":"5","key":"4503_CR6","doi-asserted-by":"publisher","first-page":"R215","DOI":"10.1530\/ERC-13-0204","volume":"20","author":"TK Day","year":"2013","unstructured":"Day TK, Bianco-Miotto T (2013) Common gene pathways and families altered by DNA methylation in breast and prostate cancers. Endocr Relat Cancer 20(5):R215\u2013R232","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4503_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijc.29684","volume":"138","author":"B Gyorffy","year":"2016","unstructured":"Gyorffy B, Bottai G, Fleischer T, Munkacsy G, Budczies J, Paladini L, Borresen-Dale AL, Kristensen VN, Santarpia L (2016) Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer 138(1):87\u201397","journal-title":"Int J Cancer"},{"issue":"2","key":"4503_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.mrrev.2012.06.001","volume":"751","author":"L Van De Voorde","year":"2012","unstructured":"Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, Speeckaert M (2012) DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 751(2):304\u2013325","journal-title":"Mutat Res"},{"issue":"3","key":"4503_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/epi.14.20","volume":"6","author":"T Wittenberger","year":"2014","unstructured":"Wittenberger T, Sleigh S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, Jones A, Evans I, Koch J, Paprotka T et al (2014) DNA methylation markers for early detection of women\u2019s cancer: promise and challenges. Epigenomics 6(3):311\u2013327","journal-title":"Epigenomics"},{"key":"4503_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/srep01389","volume":"3","author":"J Shim","year":"2013","unstructured":"Shim J, Humphreys GI, Venkatesan BM, Munz JM, Zou X, Sathe C, Schulten K, Kosari F, Nardulli AM, Vasmatzis G et al (2013) Detection and quantification of methylation in DNA using solid-state nanopores. Sci Rep 3:1389","journal-title":"Sci Rep"},{"key":"4503_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13072-016-0075-3","volume":"9","author":"WS Yong","year":"2016","unstructured":"Yong WS, Hsu FM, Chen PY (2016) Profiling genome-wide DNA methylation. Epigenet Chromatin 9:26","journal-title":"Epigenet Chromatin"},{"key":"4503_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot094839","author":"PM Lizardi","year":"2016","unstructured":"Lizardi PM, Yan Q, Wajapeyee N (2016) DNA bisulfite sequencing for single-nucleotide-resolution DNA methylation detection. Cold Spring Harb Protoc. doi:10.1101\/pdb.prot094839","journal-title":"Cold Spring Harb Protoc"},{"issue":"13","key":"4503_CR13","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/0008-5472.CAN-03-3341","volume":"64","author":"MJ Fackler","year":"2004","unstructured":"Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S (2004) Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64(13):4442\u20134452","journal-title":"Cancer Res"},{"issue":"8","key":"4503_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/1940-6207.CAPR-15-0377","volume":"9","author":"V Stearns","year":"2016","unstructured":"Stearns V, Fackler MJ, Hafeez S, Bujanda ZL, Chatterton RT, Jacobs LK, Khouri NF, Ivancic D, Kenney K, Shehata C et al (2016) Gene methylation and cytological atypia in random fine-needle aspirates for assessment of breast cancer risk. Cancer Prev Res (Phila) 9(8):673\u2013682","journal-title":"Cancer Prev Res (Phila)"},{"issue":"11","key":"4503_CR15","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1158\/1078-0432.CCR-08-1981","volume":"15","author":"MJ Fackler","year":"2009","unstructured":"Fackler MJ, Rivers A, Teo WW, Mangat A, Taylor E, Zhang Z, Goodman S, Argani P, Nayar R, Susnik B et al (2009) Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res 15(11):3802\u20133811","journal-title":"Clin Cancer Res"},{"issue":"11 Pt 1","key":"4503_CR16","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/1078-0432.CCR-05-2733","volume":"12","author":"MJ Fackler","year":"2006","unstructured":"Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA et al (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11 Pt 1):3306\u20133310","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4503_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ana.21044","volume":"60","author":"S Everhard","year":"2006","unstructured":"Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K et al (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60(6):740\u2013743","journal-title":"Ann Neurol"},{"issue":"11","key":"4503_CR18","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-07-4557","volume":"14","author":"H Fiegl","year":"2008","unstructured":"Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G et al (2008) Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 14(11):3494\u20133502","journal-title":"Clin Cancer Res"},{"key":"4503_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1476-4598-9-68","volume":"9","author":"E Dejeux","year":"2010","unstructured":"Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Borresen-Dale AL, Lonning PE, Kristensen VN et al (2010) DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9:68","journal-title":"Mol Cancer"},{"issue":"24","key":"4503_CR20","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.1158\/1078-0432.CCR-14-0297","volume":"20","author":"J Klajic","year":"2014","unstructured":"Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Borresen-Dale AL, Lonning PE, Tost J, Kristensen VN (2014) DNA methylation status of key cell-cycle regulators such as CDKNA2\/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. Clin Cancer Res 20(24):6357\u20136366","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4503_CR21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-13-3392","volume":"74","author":"MJ Fackler","year":"2014","unstructured":"Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C et al (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74(8):2160\u20132170","journal-title":"Cancer Res"},{"issue":"7","key":"4503_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2015.66.2080","volume":"35","author":"K Visvanathan","year":"2017","unstructured":"Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM et al (2017) Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study. J Clin Oncol 35(7):751\u2013758","journal-title":"J Clin Oncol"},{"issue":"7","key":"4503_CR23","doi-asserted-by":"publisher","first-page":"E1166","DOI":"10.1002\/ijc.27526","volume":"131","author":"A Avraham","year":"2012","unstructured":"Avraham A, Uhlmann R, Shperber A, Birnbaum M, Sandbank J, Sella A, Sukumar S, Evron E (2012) Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131(7):E1166\u2013E1172","journal-title":"Int J Cancer"},{"key":"4503_CR24","doi-asserted-by":"publisher","first-page":"986024","DOI":"10.1155\/2015\/986024","volume":"2015","author":"S Kristiansen","year":"2015","unstructured":"Kristiansen S, Jorgensen LM, Hansen MH, Nielsen D, Soletormos G (2015) Concordance of hypermethylated DNA and the tumor markers CA 15-3, CEA, and TPA in serum during monitoring of patients with advanced breast cancer. Biomed Res Int 2015:986024","journal-title":"Biomed Res Int"},{"key":"4503_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13148-016-0199-0","volume":"8","author":"S Kristiansen","year":"2016","unstructured":"Kristiansen S, Nielsen D, Soletormos G (2016) Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer. Clin Epigenet 8:35","journal-title":"Clin Epigenet"},{"issue":"Suppl 1","key":"4503_CR26","first-page":"S2217","volume":"26","author":"L Liu","year":"2015","unstructured":"Liu L, Sun L, Li C, Li X, Zhang Y, Yu Y, Xia W (2015) Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients. Biomed Mater Eng 26(Suppl 1):S2217\u2013S2222","journal-title":"Biomed Mater Eng"},{"issue":"6","key":"4503_CR27","doi-asserted-by":"publisher","first-page":"9794","DOI":"10.18632\/oncotarget.14216","volume":"8","author":"B Xia","year":"2017","unstructured":"Xia B, Shan M, Wang J, Zhong Z, Geng J, He X, Vu T, Zhang D, Pang D (2017) Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. Oncotarget 8(6):9794\u20139805","journal-title":"Oncotarget"},{"issue":"1","key":"4503_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2967\/jnumed.114.144741","volume":"56","author":"RM Connolly","year":"2015","unstructured":"Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, Joo HO, Carpenter J, Storniolo AM et al (2015) TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med 56(1):31\u201337","journal-title":"J Nucl Med"},{"issue":"19","key":"4503_CR29","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/0008-5472.CAN-11-1630","volume":"71","author":"MJ Fackler","year":"2011","unstructured":"Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K et al (2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71(19):6195\u20136207","journal-title":"Cancer Res"},{"issue":"34","key":"4503_CR30","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1200\/JCO.2012.42.6858","volume":"30","author":"LM McShane","year":"2012","unstructured":"McShane LM, Hayes DF (2012) Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 30(34):4223\u20134232","journal-title":"J Clin Oncol"},{"issue":"35","key":"4503_CR31","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1038\/sj.onc.1205606","volume":"21","author":"M Widschwendter","year":"2002","unstructured":"Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21(35):5462\u20135482","journal-title":"Oncogene"},{"issue":"3\u20134","key":"4503_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10911-012-9263-3","volume":"17","author":"R Connolly","year":"2012","unstructured":"Connolly R, Stearns V (2012) Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 17(3\u20134):191\u2013204","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"17","key":"4503_CR33","doi-asserted-by":"publisher","first-page":"24778","DOI":"10.18632\/oncotarget.8352","volume":"7","author":"JS de Groot","year":"2016","unstructured":"de Groot JS, Moelans CB, Elias SG, Jo Fackler M, van Domselaar R, Suijkerbuijk KP, Witkamp AJ, Sukumar S, van Diest PJ, van der Wall E (2016) DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget 7(17):24778\u201324791","journal-title":"Oncotarget"},{"issue":"3","key":"4503_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1593\/tlo.13244","volume":"6","author":"V Kajabova","year":"2013","unstructured":"Kajabova V, Smolkova B, Zmetakova I, Sebova K, Krivulcik T, Bella V, Kajo K, Machalekova K, Fridrichova I (2013) RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients. Transl Oncol 6(3):297\u2013304","journal-title":"Transl Oncol"},{"issue":"1","key":"4503_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/CBM-2012-0230","volume":"10","author":"K Sebova","year":"2011","unstructured":"Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, Lasabova Z, Tomka M, Galbavy S et al (2011) RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 10(1):13\u201326","journal-title":"Cancer Biomark"},{"issue":"3","key":"4503_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1155\/2010\/185219","volume":"33","author":"KP Suijkerbuijk","year":"2010","unstructured":"Suijkerbuijk KP, Pan X, van der Wall E, van Diest PJ, Vooijs M (2010) Comparison of different promoter methylation assays in breast cancer. Anal Cell Pathol (Amst) 33(3):133\u2013141","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"10","key":"4503_CR37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4161\/cbt.11.10.15177","volume":"11","author":"T Swift-Scanlan","year":"2011","unstructured":"Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S (2011) Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 11(10):853\u2013865","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"4503_CR38","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-13-2933","volume":"20","author":"JA Beaver","year":"2014","unstructured":"Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, Wong HY, Valda Toro P, Cidado J, Blair BG et al (2014) Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20(10):2643\u20132650","journal-title":"Clin Cancer Res"},{"issue":"302","key":"4503_CR39","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I et al (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7(302):302ra133","journal-title":"Sci Transl Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-017-4503-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4503-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4503-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:47:03Z","timestamp":1628596023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-017-4503-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4503"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4503-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,16]]},"assertion":[{"value":"5 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Women enrolling in the study signed an informed consent approved by the Institutional Review Boards of participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"VS has received research Grants from Merck, Celgene Corporation, Abbvie, Pfizer, Novartis, Medimmune, and Puma Biotechnology. RC has received research Grants from Novartis, Puma Biotechnology, Genentech, Merrimack, Clovis, Merck. AMS has received consulting fees from Eli Lilly and Co., and Pfizer. SS has received research Grants from AVON Foundation, Grants, licensing\/royalty fees and consulting fees from Cepheid for QM-MSP and cMethDNA assays. MJF has received licensing\/royalty fees and consulting fees from Cepheid. The remaining authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}